stars 1 stars 2 stars 3

Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease: oncology (failure rate of 29.5%), neurology (failure rate of 14%), and infectious diseases (failure rate of 9.5%). Pharmaceutical companies attribute this attrition to transposability between in vitro and in vivo studies, highlighting the need for new predictive models. AZELEAD responds to this need by providing innovative solutions in these key therapeutic areas. The models are developed using zebrafish, a totally transparent fish to visualize in real time the effectiveness of a drug and its side effects on the body. We are at your disposal to study together your needs and best meet your expectations!

AZELEAD Questions

The AZELEAD annual revenue was $200000 in 2026.

AZELEAD is based in Montpellier, Occitanie.

The NAICS codes for AZELEAD are [541, 5417, 54171, 54, 541711].

The SIC codes for AZELEAD are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users